The pharmacological inhibition of TGF-β with the monoclonal antibody 1D11, and the genetic overexpression of sTβRII, a soluble TGF-β type II receptor, improved tumor vessel perfusion and intratumoral distribution of chemotherapy drugs [186]. Here, TGFB1 is linked to neoplasm.